LEGAL PROCEEDINGS
−Removed: time to time, we are subject to ordinary routine litigation incidental to our normal business operations.
−Removed: We are not currently
−Removed: a party to, and our property is not subject to, any material legal proceedings, except as set forth below.
+Added: From time to time, we are
+Added: subject to ordinary routine litigation incidental to our normal business operations.
+Added: We are not currently a party to, and our property
+Added: is not subject to, any material legal proceedings, except as set forth below.
On October 25, 2017, Genexosome
13 unchanged sentences
Zhou 400 shares of common stock of Genexosome.
−Removed: Company had not been able to realize the financial projections provided by Dr.
−Removed: Zhou for the sale of the separation systems which
−Removed: were provided to the Company at the time of the acquisition and the Company has decided to impair the intangible asset associated
−Removed: with this acquisition to zero.
+Added: Further, The Company
+Added: had not been able to realize the financial projections provided by Dr.
+Added: Zhou for the sale of the separation systems which were provided
+Added: to the Company at the time of the acquisition and the Company has decided to impair the intangible asset associated with this acquisition
Zhou was terminated as Co-CEO of Genexosome on August 14, 2019.
−Removed: October 28, 2019, Research Institute at Nationwide Children’s Hospital (“Research Institute”) filed a Complaint
−Removed: in the United States District Court for the Southern District of Ohio Eastern Division against Dr.
−Removed: Zhou, Li Chen, the Company and
−Removed: Genexosome with various claims against the Company and Genexosome including misappropriation of trade secrets in violation of the
−Removed: Defend Trade Secrets Act of 2016 and violation of Ohio Uniform Trade Secrets Act.
−Removed: Research Institute is seeking monetary
−Removed: damages, injunctive relief, exemplary damages, injunctive relief and other equitable relief.
+Added: Further, on October 28, 2019, Research
+Added: Institute at Nationwide Children’s Hospital (“Research Institute”) filed a Complaint in the United States District
+Added: Court for the Southern District of Ohio Eastern Division against Dr.
+Added: Zhou, Li Chen, the Company and Genexosome with various claims
+Added: against the Company and Genexosome including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of
+Added: 2016 and violation of Ohio Uniform Trade Secrets Act.
+Added: Research Institute is seeking monetary damages, injunctive relief,
+Added: exemplary damages, injunctive relief and other equitable relief.
The case number is 2:19-cv-4574.
−Removed: The Company intends to vigorously defend against this action and pursue all available legal remedies.
−Removed: While there can
−Removed: be no assurances, the Company believes it has substantial legal and factual defenses to the Research Institute’s claims.
+Added: The Company intends to vigorously
+Added: defend against this action and pursue all available legal remedies.
+Added: While there can be no assurances, the Company believes it
+Added: has substantial legal and factual defenses to the Research Institute’s claims.
MINE SAFETY DISCLOSURES
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.